

Rec'd PCT/PTO 07 FEB 2006

Attorney Docket No.: 021305-003610US
Client Ref. No.: 010-027-USC7

10/542312 TO/SB/01A (09-04)

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS
-------------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/542,312, filed on July 15, 2005,
- ☒ as amended on July 15, 2005 (if applicable);


I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

1-00
v9
Inventor one: George Tidmarsh  Date: _____
Signature: _____ Citizen of: United States

v9
Inventor two: Harold E. Selick Date: _____
Signature: _____ Citizen of: United States

Inventor three: _____ Date: _____
Signature: _____ Citizen of: _____

Inventor four: _____ Date: _____
Signature: _____ Citizen of: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

Attorney Docket No.: 021305-003610US
Client Ref. No.: 010-027-USC7

10/542312

PTO/SB/01A (09-04)

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

FEB 07 2006

Title of
Invention

TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/542,312, filed on July 15, 2005,
- ☒ as amended on July 15, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: George Tidmarsh

Date:

Signature:

Citizen of: United States

Inventor two: Harold E. Selick

Date: 1/16/06

Signature: [Signature]

Citizen of: United States

Inventor three:

Date:

Signature:

Citizen of:

Inventor four:


Date:

Signature:

Citizen of:

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

Rec'd PCT/PTO 07 FEB 2006
10/542312 PTO/SB/81 (04-05)



**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/542,312
Filing Date	July 15, 2005
First Named Inventor	Tidmarsh, George
Title	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	021305-003610US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

20350

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Signature

Date

Name

Kevin

Kevin Kaster


Telephone

Title and Company

Vice President, Intellectual Property - Threshold Pharmaceuticals, Inc.

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: George TIDMARSH et al.Application No./Patent No.: 10/542,312 Filed/Issue Date: July 15, 2005Entitled: TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS

Threshold Pharmaceuticals, Inc., a Delaware corporation
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
 The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 017053, Frame 0825, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To : _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To : _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To : _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


 Signature
Kevin Kaster

3 Jan 06
 Date

 Printed or Typed Name
Vice President, Intellectual Property
 Title

 Telephone Number